Cargando…

Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) target HIV-1 reverse transcriptase (RT) by binding to a pocket in RT that is close to, but distinct, from the DNA polymerase active site and prevent the synthesis of viral cDNA. NNRTIs, in particular, those that are potent inhibitors of RT poly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Figueiredo, Anna, Moore, Katie L, Mak, Johnson, Sluis-Cremer, Nicolas, de Bethune, Marie-Pierre, Tachedjian, Gilda
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1635531/ https://www.ncbi.nlm.nih.gov/pubmed/17096588 http://dx.doi.org/10.1371/journal.ppat.0020119

Ejemplares similares

The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Sluis-Cremer, Nicolas
Publicado: (2014)

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors
por: Jiang, Xiangyi, et al.
Publicado: (2023)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations
por: Telwatte, Sushama, et al.
Publicado: (2015)

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism
por: Das, Kalyan, et al.
Publicado: (2012)

Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring
por: Paneth, Agata, et al.
Publicado: (2019)

Investigation of the solvent-dependent photolysis of a nonnucleoside reverse-transcriptase inhibitor, antiviral agent efavirenz
por: Jordaan, Maryam A, et al.
Publicado: (2017)

N(1),N(3)-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase
por: Novikov, Mikhail S., et al.
Publicado: (2013)

Specific reverse transcriptase slippage at the HIV ribosomal frameshift sequence: potential implications for modulation of GagPol synthesis
por: Penno, Christophe, et al.
Publicado: (2017)

N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance
por: Yap, Soo-Huey, et al.
Publicado: (2007)

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
por: Cha, Yu-Jung, et al.
Publicado: (2014)

Human Transbodies to Reverse Transcriptase Connection Subdomain of HIV-1 Gag-Pol Polyprotein Reduce Infectiousness of the Virus Progeny
por: Seesuay, Watee, et al.
Publicado: (2021)

Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase
por: Radzio, Jessica, et al.
Publicado: (2011)

What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?
por: Paneth, Agata, et al.
Publicado: (2017)

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach
por: Mansouri, Mahta, et al.
Publicado: (2023)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Schauer, Grant, et al.
Publicado: (2013)

Response to Therapy in Antiretroviral Therapy–Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor–Associated Transmitted Drug Resistance
por: Clutter, Dana S., et al.
Publicado: (2016)

Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
por: Karamchand, Sumanth, et al.
Publicado: (2016)

Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs
por: Boyer, Paul L., et al.
Publicado: (2019)

Large Multidomain Protein NMR: HIV-1 Reverse Transcriptase Precursor in Solution
por: Ilina, Tatiana V., et al.
Publicado: (2020)

FRET analysis of HIV‐1 Gag and GagPol interactions
por: Takagi, Shimon, et al.
Publicado: (2017)

Dyslipidemia among HIV-infected Patients with Tuberculosis Taking Once-daily Nonnucleoside Reverse-Transcriptase Inhibitor–Based Antiretroviral Therapy in India
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2011)

Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors
por: Liu, Genyan, et al.
Publicado: (2018)

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor
por: Gillespie, Gillian, et al.
Publicado: (2021)

Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence
por: Schauer, Grant D., et al.
Publicado: (2014)

Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance
por: Korniy, Natalia, et al.
Publicado: (2019)

Effects of reduced gag cleavage efficiency on HIV-1 Gag-Pol package
por: Lin, Yi-Ru, et al.
Publicado: (2022)

The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site
por: Abram, Michael E, et al.
Publicado: (2010)

Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
por: Lake, Jordan E., et al.
Publicado: (2015)

HIV Pol Inhibits HIV Budding and Mediates the Severe Budding Defect of Gag-Pol
por: Gan, Xin, et al.
Publicado: (2012)

The RNA binding protein HuR does not interact directly with HIV-1 reverse transcriptase and does not affect reverse transcription in vitro
por: Ahn, Jinwoo, et al.
Publicado: (2010)

Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)
por: Brown, Jennifer A., et al.
Publicado: (2021)

A Rev-Independent gag/pol Eliminates Detectable psi-gag Recombination in Lentiviral Vectors
por: Tareen, Semih U., et al.
Publicado: (2013)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
por: Wong, Alexander, et al.
Publicado: (2019)

Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis
por: Bertagnolio, Silvia, et al.
Publicado: (2020)

A purine-rich element in foamy virus pol regulates env splicing and gag/pol expression
por: Moschall, Rebecca, et al.
Publicado: (2017)

Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase
por: Brehm, Jessica H., et al.
Publicado: (2012)

Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
por: Geretti, Anna Maria, et al.
Publicado: (2013)

Enhancement of ribosomal frameshifting by oligonucleotides targeted to the HIV gag-pol region.
por: Vickers, T A, et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_kavh0h247iiu176obceilleseu